Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: Analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

Chest

Volumn 143, Issue 4, 2013, Pages 955-962

  Fazio, Nicola ^a   Granberg, Dan ^b   Grossman, Ashley ^c   Saletan, Stephen ^d   Klimovsky, Judith ^d   Panneerselvam, Ashok ^d   Wolin, Edward M ^e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EVEROLIMUS; OCTREOTIDE; PLACEBO;

ADULT; ADVANCED CANCER; ADVANCED LUNG NEUROENDOCRINE TUMOR; AGED; ANEMIA; APPETITE; ARTICLE; ASTHENIA; CAUSE OF DEATH; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; ERYTHEMA; EXPLORATORY RESEARCH; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; IMMUNE DEFICIENCY; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIVER FUNCTION; LONG ACTING REPEATABLE; LUNG FIBROSIS; LUNG INFECTION; LUNG NEUROENDOCRINE TUMOR; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK REDUCTION; SEPSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; WEIGHT;

EID: 84875989281     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1108     Document Type: Article

References (26)

1. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39 (6): 707 - 712.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26 (18): 3063 - 3072.
3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97 (4): 934 - 959.
4. Rekhtman N. Neuroendrine tumors of the lung: an update. Arch Pathol Lab Med. 2010; 123 (11): 1628 - 1638.
5. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. The concept of pulmonary neuroendocrine tumours. In: Pathology&Genetics: Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours. Lyon, France : IARC Press; 2004 : 19 - 20.
6. Oberg K, Akerström G, Rindi G, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v223 - v227.
7. Phan AT, Oberg K, Choi J, et al North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010; 39 (6): 784 - 798.
8. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007; 13 (10): 2986 - 2991.
9. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010; 31 (2): 169 - 188.
10. Rinke A, Müller HH, Schade-Brittinger C, et al PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27 (28): 4656 - 4663.
11. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008; 26 (8): 1316 - 1323.
12. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008; 26 (20): 3403 - 3410.
13. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to inter-mediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008; 26 (26): 4311 - 4318.
14. Zatelli MC, Minoia M, Martini C, et al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer. 2010; 17 (3): 719 - 729.
15. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006; 17 (12): 1733 - 1742.
16. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378 (9808): 2005 - 2012.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Can cer, National Cancer Institute of the United States, National Can cer Institute of Canada. J Natl Cancer Inst. 2000; 92 (3): 205 - 216.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5 (6): 649 - 655.
19. Yao JC, Hainsworth JD, Wolin EM, et al. Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or pla cebo (P+O) among patients with advanced neuroendocrine tumors (NET) [abstract]. J Clin Oncol. 2012; 30 (suppl 4): 157.
20. National Institutes of Health Clinical Center. 3-Arm trial to evaluate pasireotide LAR/everolimus alone/in combination in patients with lung/thymus NET (MACS1328). NCT01563354. Clinicaltrials.gov. Bethesda, MD: National Institutes of Health; 2012. http://clinicaltrials.gov/ct2/show/NCT01563354. Updated March 26, 2012.
21. Righi L, Volante M, Tavaglione V, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol. 2010; 21 (3): 548 - 555.
22. Righi L, Volante M, Rapa I, et al. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer. 2010; 17 (4): 977 - 987.
23. McCaughan BC, Martini N, Bains MS. Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg. 1985; 89 (1): 8 - 17.
24. Soga J, Yakuwa Y. Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. 1999; 5 (4): 211 - 219.
25. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010; 134 (11): 1628 - 1638.
26. Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol. 2001; 12 (10): 1383 - 1391